Ipragliflozin (ASP1941) is an orally active and selective inhibitor of SGLT2, with IC50s of 7.38 and 1876 nM for human SGLT2 and SGLT1, respectively. It serves as an antidiabetic agent[1].
Ipragliflozin/伊格列净 动物研究
Animal study
Ipragliflozin exhibits antihyperglycemic effects, with dose-dependent inhibition of increases in blood glucose levels. In both STZ-induced type 1 diabetic rats and KK-Ay type 2 diabetic mice, this effect is significant at various tested doses[1].In streptozotocin-induced type 1 diabetic rats, repeated administration of Ipragliflozin (0.3 and 1 mg/kg) demonstrates antidiabetic effects[1].In Streptozotocin (STZ; 50 mg/kg)-induced type 1 diabetic rats and KK-Ay type 2 diabetic mice, doses ranging from 0.1 to 1 mg/kg were orally administered once in the fed state. Blood glucose levels were then monitored for 8 hours under fasting conditions. The results indicated a dose-dependent reduction in blood glucose levels, which was statistically significant at all tested doses. This experiment utilized a repeated administration animal model[1].In Streptozotocin (STZ; 50 mg/kg)-induced type 1 diabetic rats, doses of 0.3 and 1 mg/kg were orally administered once daily at night for 4 weeks. The outcome revealed significant reductions in both HbA1c and blood glucose levels. Furthermore, pancreatic insulin content significantly increased at a dose of 1 mg/kg. Urinary glucose excretion exhibited a dose-dependent increase, reaching significance at the 1 mg/kg dose[1].
搜索
